Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive transcriptomic profiles of human induced pluripotent stem cells or human embryonic stem cells exposed to bisphenol A or thalidomide

ABSTRACT: In this study, we examined the epigenetic toxicity of bisphenol A and thalidomide, focusing on their effects on cellular differentiation and gene expression. Thalidomide promoted ectodermal differentiation at the expense of other lineages, while bisphenol A had milder effects. Transcriptome analysis revealed distinct gene expression changes for each chemical, with thalidomide inducing more pronounced shifts. These changes correlated with increased H3K27ac modifications at enhancer regions of upregulated genes, linking gene expression alterations to epigenetic modifications. The findings emphasize the role of epigenetic mechanisms in developmental toxicity.

ORGANISM(S): Homo sapiens

PROVIDER: GSE279680 | GEO | 2026/08/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Comprehensive H3K27ac modification profiles of human induced pluripotent stem cells or human embryonic stem cells exposed to bisphenol A or thalidomide

Project description:In this study, we examined the epigenetic toxicity of bisphenol A and thalidomide, focusing on their effects on cellular differentiation and gene expression. Thalidomide promoted ectodermal differentiation at the expense of other lineages, while bisphenol A had milder effects. Transcriptome analysis revealed distinct gene expression changes for each chemical, with thalidomide inducing more pronounced shifts. These changes correlated with increased H3K27ac modifications at enhancer regions of upregulated genes, linking gene expression alterations to epigenetic modifications. The findings emphasize the role of epigenetic mechanisms in developmental toxicity.

2026-08-12 | GSE279681 | GEO

Thalidomide induced early gene expression perturbations indicative of human embryopathy in mouse embryonic stem cells

Project description:To unravel the mechanisms of thalidomide developmental toxicity, we used microarrays to study transcriptomic changes induced by thalidomide during mouse embryonic stem cell (mESC) differentiation. C57BL/6 mESCs were allowed to differentiate spontaneously and global gene expression changes were studied using microarrays at at different time points after exposure to 0.25 mM thalidomide (THD).

2015-05-31 | GSE61306 | GEO

Thalidomide Exerts Distinct Molecular Antileukemic Effects

Project description:Thalidomide Exerts Distinct Molecular Antileukemic Effects and Combined Thalidomide/Fludarabine Therapy is Clinically Effective in High-Risk Chronic Lymphocytic Leukemia Background: Thalidomide represents a promising immunomodulatory drug that targets both leukemia cells and the tumor microenvironment. Methods: We treated chronic lymphocytic leukemia (CLL) patients with a combined thalidomide/fludarabine regimen and monitored cellular and molecular changes induced by thalidomide in-vivo prior to fludarabine treatment. Thalidomide was given daily (100mg p.o./day) and fludarabine was administered on days 7-11 (25 mg/m² i.v./day) within each 4-week cycle (maximum of 6 cycles). Twenty patients received thalidomide/fludarabine as first line therapy and 20 patients were previously treated. Unmutated IgVH mutation status was found in 36 cases and 13 had high-risk cytogenetic aberrations (deletion of 17p13 or 11q22-q23). Results: The overall response rate was 80% and 25% for untreated and previously treated patients, respectively. While thalidomide effectively reduced the number of CLL cells, the number of CD3 lymphocytes showed no significant change, but the number of CD4+CD25hiFOXP3+ T-regulatory cells was significantly decreased. Gene expression profiling revealed a thalidomide induced signature containing both targets known to play a role in immunomodulatory drug action as well as novel candidate genes. Conclusions: Combined thalidomide/fludarabine therapy demonstrated efficacy in high-risk CLL patients. Furthermore, our study provides novel biological insights into thalidomide effect, which might act by enhancing apoptosis of CLL cells and reducing Tregs, thereby enabling T-cell dependent anti-tumor effect.

2009-08-21 | GSE15913 | GEO

Comprehensive transcriptomic profiles of human induced pluripotent stem cells or human embryonic stem cells exposed to bisphenol A or thalidomide

Project description:Comprehensive transcriptomic profiles of human induced pluripotent stem cells or human embryonic stem cells exposed to bisphenol A or thalidomide

| PRJNA1174081 | ENA

Identification of thalidomide modulation related genes in mesenchymal stem cells

Project description:Comparison of gene expression data from thalidomide modulated- and unmodulated-MSCs from patients with idiopathic thrombocytopenic purpura (ITP).

2013-03-12 | GSE44948 | GEO

Comprehensive H3K27ac modification profiles of human induced pluripotent stem cells or human embryonic stem cells exposed to bisphenol A or thalidomide

Project description:Comprehensive H3K27ac modification profiles of human induced pluripotent stem cells or human embryonic stem cells exposed to bisphenol A or thalidomide

| PRJNA1174077 | ENA

Comparative analysis between effects of thalidomide and environmental chemicals on neuronal differentiations in human sphere

Project description:To develop molecular indicators of neurodevelopmental disorders related to the exposure to external chemicals, we have employed whole genome microarray expression profiling as a discovery platform to identify genes with the potential to influence neuronal differentiation from embryonic stem cells. Thalidomide (TMD), bisphenol A (BPA), 4-hydroxy-2,2',3,4',5,5',6-heptachlorobiphenyl (4OH-PCB187) and 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) were exposed to human embryonic stem (ES) cell-derived sphere on day 3 after starting sphere formation for 72 hours. Gene expression analysis on the stage of sphere development showed chemical specific characteristics.

2020-05-28 | GSE151239 | GEO

Identification of thalidomide modulation related genes in mesenchymal stem cells

Project description:Comparison of gene expression data from thalidomide modulated- and unmodulated-MSCs from patients with idiopathic thrombocytopenic purpura (ITP). This experiment consists of 3 arrays.

2013-03-12 | E-GEOD-44948 | biostudies-arrayexpress

Transcriptome analysis of bisphenol A (BPA) treated Y79 human retinoblastoma cells

Project description:Purpose: finding differential transcripts usage in environmentally harzardous chemical, bisphenol A (BPA) in human retinal cells Methods: transcriptome analysis by the RNA-seq via mRNA pull-down Results: We found that BPA increases cellular toxicity by the increasing of early apoptotic pathway in Y79 cells. Also, over thounds of retained intron events were detected from the RNA-seq analysis. Conclusions: Bisphenol A (BPA) increases early cytotoxic effects in Y79 cells through the early apoptotic pathway and changes the context of trascript through the splicing regulation mechanisms.

2021-02-16 | GSE146255 | GEO

Thalidomide Reverses Sporadic Arteriovenous Malformation in the Central Nervous System

Project description:Sporadic arteriovenous malformations of the central nervous system (CNS-AVMs) are caused by somatic activating mutations of KRAS within endothelial cells (ECs) of the brain and spinal cord. There is no approved drug for this disease because the lack of a clinically representative animal model has hindered drug discovery. Here, we developed a novel mouse model of sporadic brain AVM (BAVM) induced by intracerebral injection of AAV-BR1-KRASG12V. This model faithfully recapitulates the clinical manifestations, radiology, pathology, and transcriptomic profiles of human sporadic BAVM. Connectivity Map database analysis revealed thalidomide as a promising therapeutic. Preclinical experiments revealed that thalidomide can restore mural cell coverage with downregulating Angiopoietin 2 (ANGPT2) in ECs and inhibiting BAVM progression. This effect reduced hemorrhage and prolonged the survival of mice with BAVM. We then administered thalidomide to 30 patients with sporadic CNS-AVMs. Over a median treatment duration of 7.3 months, AVM lesions regressed in 60.7% of patients, while symptoms improved in 10.7%. Biopsies demonstrated that thalidomide increased mural cell coverage and decreased ANGPT2 expression in ECs within AVM lesions. In summary, we established a representative model of sporadic BAVM and provided promising evidence supporting the therapeutic potential of thalidomide for sporadic CNS-AVMs.

2026-07-31 | GSE305291 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data